This webinar covered the impact of price transparency reporting thus far. Panelists discussed what additional efforts are necessary to provide consumers with accurate information to make more informed decisions.
Perhaps not unexpectedly, the early days of federally mandated price transparency reporting have included data challenges, questions regarding usefulness, and in some cases simple non-compliance.
As CMS moves to strengthen their efforts by increasing fines and payers prepare for the next set of reporting requirements for covered items and service, and eventually prescription drugs, this webinar covered the impact of price transparency reporting thus far and panelists discussed what additional efforts are necessary to provide consumers with accurate and useful information to make more informed decisions regarding the costs and quality of care.
Moderator:
Niall Brennan is the Senior Advisor for Data Strategy to the CDC Director. Read Bio
Presenters:
Ceci Connolly is President and CEO of the Alliance of Community Health Plans (ACHP), the trade association for... Read Bio
John M. O'Brien, Pharm.D., M.P.H., is the president and chief executive officer of the National Pharmaceutical... Read Bio
In her role at the American Hospital Association, Molly Smith helps oversee the development of policy position... Read Bio